eligibility_summary
Eligibility: Metastatic NSCLC. Phase 1: progressed/intolerant to SOC, if no driver, had platinum plus PD-(L)1, if driver+, failed appropriate targeted, EGFR+ must have no prior PD-1/PD-L1. Phase 2: A EGFR exon19del/L858R, B no driver, PD-L1 >=50%, metastatic treatment-naive. Measurable non-irradiated lesion, ECOG 0-1. Exclude: uncontrolled illness/infection/bleeding/O2/psych, ILD/pneumonitis, active autoimmune on steroids, palliative RT <14 d, LM disease, untreated cord compression.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Amivantamab (JNJ-61186372), a bispecific IgG1 monoclonal antibody targeting EGFR and MET, IV, it blocks EGFR/MET signaling, promotes receptor internalization/degradation, and mediates Fc-dependent cytotoxicity (ADCC/ADCP). Cetrelimab (JNJ-63723283), an anti–PD-1 IgG4 monoclonal antibody checkpoint inhibitor, IV, it blocks PD-1 to restore T‑cell activation and antitumor immunity. Cells/pathways targeted: EGFR- and MET-expressing NSCLC tumor cells, PD-1 on T cells and the PD-1/PD-L1 axis. Combination aims to inhibit oncogenic EGFR/MET pathways while unleashing T-cell–mediated killing.